Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOTAL: Pharmacological Individualisation of Voriconazole Therapy
NCT01887457Phase 2Suspended
- Start
- Sep 2014
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of voriconazole in aspergillosis, fusariosis and scedosporiosis. Primary endpoint: Dose adjustment success at 5 days. Started Sep 2014; status: suspended.
02
Drugs
voriconazole
03
Conditions
aspergillosisfusariosisscedosporiosis
Beyond the preview
Go deeper on NCT01887457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01887457.